Quick Answer
PALISADE BIO, INC. reported Cash and Equivalents of $133.38 million for fiscal year 2025.
PALISADE BIO, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $133.38M | +1258.2% |
| 2024 | $9.82M | -21.0% |
| 2023 | $12.43M | +0.4% |
| 2022 | $12.38M | +18.0% |
| 2021 | $10.49M | +1371.9% |
| 2020 | $713.0K | -86.1% |
| 2019 | $5.11M | -11.6% |
| 2018 | $5.79M | -13.3% |
| 2017 | $6.67M | -56.1% |
| 2016 | $15.19M | +222.2% |
| 2015 | $4.72M | -62.3% |
| 2014 | $12.52M | -25.7% |
| 2013 | $16.85M | +126.3% |
| 2012 | $7.44M | +216.5% |
| 2011 | $2.35M | -74.6% |
| 2010 | $9.26M | +301.0% |
| 2009 | $2.31M | -52.9% |
| 2008 | $4.90M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.23M | -35.0% | -3.5% |
| June 30, 2025 | $5.42M | -52.3% | -25.1% |
| March 31, 2025 | $7.23M | -35.9% | -26.4% |
| December 31, 2024 | $9.82M | -21.0% | +22.2% |
| September 30, 2024 | $8.04M | -47.5% | -29.2% |
| June 30, 2024 | $11.35M | -30.8% | +0.7% |
| March 31, 2024 | $11.28M | -15.2% | -9.3% |
| December 31, 2023 | $12.43M | +0.4% | -18.8% |
- PALISADE BIO, INC. showed an increase of +1258.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, PALISADE BIO, INC.’s cash and equivalents has grown by 2620.3% (from $4.90 million to $133.38 million).
- The most recent figure is from PALISADE BIO, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 20, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: